Comparator: Modified Process Vaccine + Comparator: COMVAX™

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Haemophilus Influenzae Type B

Conditions

Haemophilus Influenzae Type B, Hepatitis B

Trial Timeline

Dec 1, 2006 → Jun 1, 2008

NCT ID

NCT00441012

About Comparator: Modified Process Vaccine + Comparator: COMVAX™

Comparator: Modified Process Vaccine + Comparator: COMVAX™ is a phase 3 stage product being developed by Merck for Haemophilus Influenzae Type B. The current trial status is completed. This product is registered under clinical trial identifier NCT00441012. Target conditions include Haemophilus Influenzae Type B, Hepatitis B.

What happened to similar drugs?

2 of 8 similar drugs in Haemophilus Influenzae Type B were approved

Approved (2) Terminated (0) Active (6)

✅Vaxelis + PedvaxHIBMerckApproved

✅Haemophilus influenza type b conjugate vaccineNovartisApproved

🔄Haemophilus influenzae type b (Hib) vaccineNovartisPhase 3

🔄Hib-CRM197 + Hib-TTNovartisPhase 3

🔄Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine)NovartisPhase 3

🔄Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib) + Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00441012	Phase 3	Completed	Dec 1, 2006	Jun 1, 2008	Haemophilus Influenzae Type B

Competing Products

10 competing products in Haemophilus Influenzae Type B

See all competitors

Product	Company	Stage	Hype Score
Vaxelis + PedvaxHIB	Merck	Approved	43
Haemophilus influenzae type b (Hib) vaccine	Novartis	Phase 3	40
Haemophilus influenzae type b (Hib) vaccine	Novartis	Phase 3	40
Haemophilus influenza type b conjugate vaccine	Novartis	Approved	43
Hib-CRM197 + Hib-TT	Novartis	Phase 3	40
Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine)	Novartis	Phase 3	40
Haemophilus influenzae type b	Novartis	Phase 1	29
Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib) + Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)	Novartis	Phase 3	40
Haemophilus influenzae type b vaccine + Commercial Haemophilus influenzae type b vaccine	Novartis	Phase 3	40
DTaP-IPV/Hib	Sanofi	Pre-clinical	26